Mar, 2017

Towards better medicines for children: PedCRIN project builds research infrastructure


The European Clinical Research Infrastructure Network (ECRIN) has announced the launch of the Paediatric Clinical Research Infrastructure Network (PedCRIN). The three-year project brings together ECRIN and the founding partners of the European Paediatric Clinical Trial Research Infrastructure (EPCT-RI) to develop capacity for the management of multinational paediatric clinical trials



Nov, 2016

The ZIKAction Kick-Off Meeting was a success!


The ZIKAction Kick-Off Meeting was held in Kingston, Jamaica at the University of West Indies from October 30th to November 1st. Thank you all for coming!! This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734857.



Oct, 2016

PENTA Foundation coordinated ZIKAction consortium


PENTA Foundation coordinated ZIKAction consortium awarded €7 million EU H2020 grant to combat Zika virus and other emerging infectious disease outbreaks The ZIKAction consortium (Preparedness, research and action network on maternal-paediatric axis of Zika virus infection in Latin America and the Caribbean), coordinated by the PENTA Foundation, is set to receive a €7 million, five-year grant from the European Union through the Horizon 2020 programme’s recent call for research to combat Zika virus (ZIKV) and other emerging infections transmitted by mosquitoes in Latin America. This award is one of three […]



Sep, 2014

Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines


Authors: Ruggieri L., Giannuzzi V., Baiardi P., Bonifazi F., Davies E.H., Giaquinto C. , Bonifazi D., Felisi M., Chiron C., Pressler R., Rabe H., Whitaker M.J., Neubert A., Jacqz-Aigrain E., Eichler I., Turner M.A., Ceci A; GRiP Consortium.

Published in: Eur J Pediatr. 2015, 174: 481-91.

Abstract: The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children. Responding to this mandate, five FP7 pr